LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

Search

MannKind Corp

Fermé

SecteurSoins de santé

4.59 2

Résumé

Variation du prix de l'action

24h

Actuel

Min

4.5

Max

4.61

Chiffres clés

By Trading Economics

Revenu

-12M

668K

Ventes

-1.8M

77M

P/E

Moyenne du Secteur

35.455

35.724

Marge bénéficiaire

0.873

Employés

403

EBITDA

-17M

9.7M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+105.45% upside

Dividendes

By Dow Jones

Prochains Résultats

6 nov. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

5.2M

1.2B

Ouverture précédente

2.59

Clôture précédente

4.59

Sentiment de l'Actualité

By Acuity

15%

85%

22 / 372 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bullish Evidence

MannKind Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

29 août 2025, 18:43 UTC

Principaux Mouvements du Marché

Privia Health Shares Advance on Outlook Bump From Medicare Savings

29 août 2025, 15:07 UTC

Acquisitions, Fusions, Rachats

Strathcona Resources to Increase Minority Stake in MEG Energy, Vote Against Cenovus Buyout Plan

29 août 2025, 20:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Auto & Transport Roundup: Market Talk

29 août 2025, 20:24 UTC

Résultats

Earnings Season Highlights on Tariffs, Consumer Spending, and More -- Barrons.com

29 août 2025, 20:17 UTC

Résultats

These Stocks Moved the Most Today: Alibaba, Marvell, Affirm, Nvidia, Dell, Autodesk, Ambarella, IREN, and More -- Barrons.com

29 août 2025, 19:18 UTC

Market Talk

Oil Futures End Week With Modest Gains -- Market Talk

29 août 2025, 18:59 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

29 août 2025, 18:36 UTC

Résultats

These Were the Best & Worst S&P 500 Stocks in August -- Barrons.com

29 août 2025, 18:26 UTC

Résultats

What the Stock Market Learned About Earnings and Consumers This Summer -- Barrons.com

29 août 2025, 17:48 UTC

Market Talk

U.S. Oil Rig Count Increases By 1 to 412 -- Market Talk

29 août 2025, 17:10 UTC

Market Talk
Acquisitions, Fusions, Rachats

Regulator Firing Clears Path for Union Pacific-Norfolk Southern Deal -- Market Talk

29 août 2025, 16:57 UTC

Résultats

These Stocks Are Moving the Most Today: Alibaba, Marvell, Affirm, Nvidia, Dell, Autodesk, Ambarella, IREN, and More -- Barrons.com

29 août 2025, 16:30 UTC

Acquisitions, Fusions, Rachats

Celsius Stock Is Spiking After PepsiCo Increases Stake -- Barrons.com

29 août 2025, 16:28 UTC

Acquisitions, Fusions, Rachats

BBVA: Adjustment Intended to Maintain Equivalent Economic Terms of Offer Following Dividend Payments by Sabadell

29 août 2025, 16:27 UTC

Acquisitions, Fusions, Rachats

BBVA: Adjustment Outlined in Announcement on May 9, 2024

29 août 2025, 16:26 UTC

Acquisitions, Fusions, Rachats

BBVA Now Offering 1 Newly Issued Ordinary BBVA Share and EUR0.70 in Cash for Every 5.5483 Ordinary Shares of Sabadell

29 août 2025, 16:25 UTC

Acquisitions, Fusions, Rachats

BBVA: Adjustment Factors in Interim Dividend Paid by Sabadell to Its Shareholders

29 août 2025, 16:24 UTC

Acquisitions, Fusions, Rachats

BBVA Adjusts Offer for Banco de Sabadell

29 août 2025, 16:23 UTC

Market Talk
Acquisitions, Fusions, Rachats

Strathcona's Power Play in MEG Energy Jeopardizes Cenovus Deal -- Market Talk

29 août 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

29 août 2025, 16:06 UTC

Market Talk

Gold Futures Gain as U.S. Inflation Data Boost Rate Cut Hopes -- Market Talk

29 août 2025, 15:12 UTC

Market Talk
Résultats

Best Buy Surprise Comp Growth Potentially Driven by Switch 2 -- Market Talk

29 août 2025, 15:09 UTC

Résultats

Small-Cap Stocks Are Rallying Again. This Time It's Real. -- Barrons.com

29 août 2025, 15:01 UTC

Market Talk

Canadian Economy Expected to Slow But Grow in 2H -- Market Talk

29 août 2025, 14:49 UTC

Résultats

These Stocks Are Moving the Most Today: Marvell, Dell, Nvidia, Alibaba, Affirm, Autodesk, Ambarella, IREN, and More -- Barrons.com

29 août 2025, 14:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

29 août 2025, 14:49 UTC

Market Talk

Canada May Avoid Contraction in 3Q, But Is Expected to Struggle -- Market Talk

29 août 2025, 14:48 UTC

Résultats

Marvell Stock Tumbles. Why the AI Chip Player Keeps Disappointing the Market. -- Barrons.com

29 août 2025, 14:43 UTC

Market Talk

Rise in Canadian Household Spending May Not Worry Central Bank -- Market Talk

29 août 2025, 14:38 UTC

Market Talk

With Canada's Economy Soft, Central Bank Easing Looks Likely -- Market Talk

Comparaison

Variation de prix

MannKind Corp prévision

Objectif de Prix

By TipRanks

105.45% hausse

Prévisions sur 12 Mois

Moyen 9.43 USD  105.45%

Haut 12 USD

Bas 7 USD

Basé sur 7 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

7 ratings

7

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

4.079 / 4.323Support & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Weak Bearish Evidence

Sentiment

By Acuity

22 / 372Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.